FDA approves selpercatinib for locally advanced or metastatic RET fusion positive non-small-cell lung cancer


21 September 2022 - Today, the Food and Drug Administration granted regular approval to selpercatinib (Retevmo, Eli Lilly) for adult patients with locally advanced or metastatic non-small-cell lung cancer with a rearranged during transfection (RET) gene fusion, as detected by an FDA approved test.

Today, FDA also approved the Oncomine Dx Target Test (Thermo Fisher Scientific) as a companion diagnostic for selpercatinib.

Read FDA News

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US